Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats

European Journal of Pharmacology

Volumn 555, Issue 2-3, 2007, Pages 164-173

  Malik, Nasser M ^a   Liu, Yong Ling ^a   Cole, Nicholas ^a   Sanger, Gareth J ^b   Andrews, Paul L R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cisplatin; Dexamethasone; Fatigue; Gastric stasis; GR205171; Nausea; Ondansetron; Pica; Vomiting

Indexed keywords

CISPLATIN; DEXAMETHASONE; KAOLIN; ONDANSETRON; SEROTONIN 3 ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; VOFOPITANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; DYSPEPSIA; FATIGUE; FLUID INTAKE; FOOD INTAKE; LOCOMOTION; MALAISE; MALE; NONHUMAN; PICA; PRIORITY JOURNAL; RAT; REARING; STOMACH CONTENT; STOMACH FUNCTION; VOMITING;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; EATING; GASTRIC EMPTYING; MALE; MOTOR ACTIVITY; NAUSEA; ONDANSETRON; PICA; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; TETRAZOLES;

EID: 33845978333     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.10.043     Document Type: Article

References (56)

1. Aapro M.S., and Alberts D.S. High-dose dexamethasone for the prevention of cisplatin-induced vomiting. Cancer Chemother. Pharmacol. 7 (1981) 11-14
2. Ahlberg K., Ekman T., Gaston-Johansson F., and Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 362 (2003) 40-650
3. Andrews P.L.R., and Morrow G.R. Approaches to understanding the mechanisms involved in fatigue associated with cancer and its treatments: a speculative review. In: Marty M., and Pecorelli S. (Eds). European School of Oncology Scientific Updates. Fatigue and Cancer vol. 5 (2002), Elsevier 1-15
4. 1) receptor in nausea and emesis. In: Holzer P. (Ed). Handbook of Experimental Pharmacology vol. 164 (2004), Springer, U.S.A 359-441
5. Aranda Aguilar E., Rubio Perez M.J., Gonzlez Manch R., Barneto Aranda I., and Lomas Garrido M. Puesta a punto de un modelo experimental para el estudio de antiemeticos. Neoplasia 9 (1992) 180-182
6. Beattie W.W., Scoutenm C.W., and Beattie P.A. Differential effects of dexamethasone and body weight loss on two measures of activity. Physiol. Behav. 7 (1971) 869-871
7. Broomhead J.A., Fairlie D.P., and Whitehouse M.W. cis-platinum (II) amine complexes: some structure activity relationships for immunosuppressive, nephrotoxic and gastrointestinal (side) effects in rats. Chem. Biol. Interact. 31 (1980) 113-132
8. Cairnie A.B., and Leach K.E. Dexamethasone: a potent blocker for radiation-induced taste aversion in rats. Pharmacol. Biochem. Behav. 17 (1982) 305-311
9. Carelle N., Piotto E., Bellanger A., Germanaud J., Thuillier A., and Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95 (2002) 155-163
10. Eeckhout C., and Vedder A. 5-HT3 antagonists reverse the cisplatin induced slowing of gastric emptying in fed rats. Gastroenterology 94 (1988) A111
11. Eeckhout C. Capsaicin-sensitive vagal afferent pathways mediate the effects of cisplatin on gastric emptying in the rat. J. Gastrointest. Motil. 1 (1989) A52
12. Eeckhout C. Effects of prokinetics with a different mechanism of action on cislatin-induced slowing of gastric emptying in the rat. J. Gastrointest. Motil. 1 (1989) A52
13. Ellacott K.L.J., Lawrence C.B., Rothwell N.J., and Luckman S.M. PRL-releasing peptide interacts with leptin to reduce food intake and body weight. Endocrinology 143 (2002) 368-374
14. Forster E.R., and Dockray G.J. The effect of ondansetron on gastric emptying in the conscious rat. Eur. J. Pharmacol. 191 (1990) 235-238
15. Fukunaka N., Sagae S., Kudo R., Endo T., Hirafuji M., and Minami M. Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret. Gen. Pharmacol. 31 (1998) 775-781
16. Gale D., Blakemore S.J., Cook, Kidwai S., Moore I., Moore G.B.T., Moore S.E., Sanger G.J., Holbrook J., Liu Y.-L., Malik N., and Andrews P.L.R. Modulation of gene expression in the glandular and non-glandular regions of the rat stomach after treatment with the anti-cancer drug cisplatin. Gastroenterology 128 (2005) A-545 Abstr T1762
17. Gardner C.J., Armour D.R., Beattie D.T., Gale J.D., Hawcock A.B., Kilpatrick G.J., Twissell D.J., and Ward P. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul. Pept. 65 (1996) 45-53
18. Glendinning J.I., and Smith J.C. Consistency of meal patterns in laboratory rats. Physiol. Behav. 56 (1994) 7-16
19. Hainsworth J.D., and Hesketh P.J. Single dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results. Semin. Oncol. 19 (1992) 14-19
20. Hawthorn J., and Cunningham D. Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br. J. Cancer. 61 (1990) 56-60
21. Hesketh P.J., Van Belle S., Aapro M., Tattersall F.D., Naylor R.J., Hargreaves R., Carides A.D., Evans J.K., and Horgan K.J. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur. J. Cancer 39 (2003) 1074-1080
22. Hultin L., Hyberg G., Lindsrom E., and Lehmann A. In vivo imaging of tachykinin NK1 receptor agonist induced reflux in rats. Neorogastroenterol. Motil. 17 Suppl. 2 (2005) 60
23. Ito C., Isobe Y., Tsuchida K., and Higuchi S. 5-Hydroxytryptamine3 receptor and regulation of gastric emptying in rats. Arch. Int. Pharmacodyn. Ther. 331 (1996) 203-218
24. Jarve R.K., and Aggarwal S.K. Cisplatin-induced inhibition of the calcium-calmodulin complex, neuronal nitric oxide synthase activation and their role in stomach distension. Cancer Chemother. Pharmacol. 39 (1997) 341-348
25. Konsman J.P., Parnet P., and Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 25 (2002) 154-159
26. Lalonde J., Samson P., Poulin S., Deshaies Y., and Richard D. Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol. Behav. 80 (2004) 415-420
27. Liu Y.-L., Malik N.M., Sanger G.J., Friedman M.I., and Andrews P.L.R. Pica-a model of nausea? Species differences in the response to cisplatin. Physiol. Behav. 85 (2005) 271-277
28. Liu Y.-L., Malik N.M., Sanger G.J., and Andrews P.L.R. Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother. Pharmacol. 58 (2006) 326-333
29. Malik N.M., Moore G.B.T., Smith G., Liu Y.-L., Sanger G.J., and Andrews P.L.R. Behavioural and molecular effects of the anti-cancer agent cisplatin in the rat: a model of chemotherapy-related malaise. Pharmacol. Biochem. Behav. 83 (2006) 9-20
30. Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology 53 (1996) 26-31
31. McAllister K.H., and Pratt J.A. GR205171 blocks apomorphine and amphetamine-induced conditioned taste aversions. Eur. J. Pharmacol. 353 (1998) 141-148
32. Mele P.C., McDonough J.R., McLean D.B., and O'Halloran K.P. Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not zacopride or GR38032F. Eur. J. Pharmacol. 218 (1992) 229-236
33. Moore G.B.T., Malik N., Liu R.W., and Corcoron G.L. Increased ghrelin receptor mRNA and therapeutic effects of ghrelin after acute cisplatin treatment. Neurogastroenterol. Motil. 15 (2003) A12
34. Morrow G.R., Hickok J.T., Roscoe J.A., Raubertas R.F., Andrews P.L.R., Flynn P.J., Hynes H.E., Banerjee T.K., Kirshner J.J., and King D.K. Differential effects of paroxetine on fatigue and depression: a randomized, double blind trial from the University of Rochester Cancer Centre Community Oncology Program. J. Clin. Oncol. 21 (2003) 4635-4641
35. Neary N.M., Samll C.J., Druce M.R.., Park A.J., Ellis S.M., Semjonous N.M., Dakin C.J., Filipsson K., Wang F., Kent A.S., Frost G.S., Ghatei M.A., and Bloom S.R. Peptide YY-3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146 (2005) 5120-5127
36. Nelson K., Walsh D., and Sheehan F. Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients. Support. Care Cancer 10 (2002) 455-461
37. 3 receptor antagonist. Gen. Pharmacol. 33 (1999) 283-288
38. Revusky S., and Martin G.M. Glucocorticoids attenuate taste aversions produced by toxins in rats. Psychopharmacology (Berl) 96 (1988) 400-407
39. Roos I.A., Fairlie D.P., and Whitehouse M.W. A peculiar toxicity manifested by platinum (II) amines in rats: gastric distension after intraperitoneal administration. Chem. Biol. Interact. 35 (1981) 111-117
40. Roscoe J.A., Morrow G.R., Hickok J.T., Bushunow P., Matteson S., Rakita D., and Andrews P.L.R. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support. Care Cancer 10 (2002) 329-336
41. Rubio Perez M.J., Aranda Aguilar E., Barneto Aranda I., Lomas Garrido M., and Gonzalez Mancha R. Efficacia antiemetica de la metoclopramida en la dilatacion gastrica inducida por cisplatino en ratas Wistar. Neoplasia 10 (1992) 40-43
42. Rudd J.A., and Naylor R.J. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br. J. Pharmacol. 118 (1996) 209-214
43. Rudd J.A., Jordan C.C., and Naylor R.J. The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br. J. Pharmacol. 119 (1996) 931-936
44. Rudd J.A., Ngan M.P., and Wai M.K. 5-HT3 receptors are not involved in conditioned taste aversions induced by 5-hydroxytryptamine, ipecacuanha or cisplatin. Eur. J. Pharmacol. 352 (1998) 143-149
45. Rudd J.A., Yamamoto K., Yamatodani A., and Takeda N. Differential action of ondansetron and dexamethasone to modify cisplatin-induced acute and delayed kaolin consumption ("pica") in rats. Eur. J. Pharmacol. 454 (2002) 47-52
46. Saeki M., Sakai M., Saito R., Kubota H., Ariumi H., Takano Y., Yamatodani A., and Kamiya H. Effects of HSP-117, a novel tachykinin NK1-receptor antagonist, on cisplatin-induced pica as a new evaluation of delayed emesis in rats. Jpn. J. Pharmacol. 86 (2001) 359-362
47. Sanger G.J. Neurokin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br. J. Pharmacol. 141 (2004) 1-10
48. Sharma S.S., and Gupta Y.K. Reversal of cisplatin-induced delay in gastric emptying in rats by ginger (Zingiber officinale). J. Ethnopharmacol. 62 (1998) 49-55
49. Stone P., Richards M., and Hardy J. Fatigue in patients with cancer. Eur. J. Cancer 34 (1998) 1670-1676
50. Stone P., Hardy J., Broadley K., Tookman A.J., Kurowska A., and A'Hern R. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br. J. Cancer 79 (1999) 1479-1486
51. Stone P., Richardson A., Ream E., Smith A.G., Kerr D.J., and Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann. Oncol.11 (2000) 971-975
52. Takeda N., Hasegawa S., Morita M., and Matsunaga T. Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol. Biochem. Behav. 45 (1993) 817-821
53. Takeda N., Hasegawa S., Morita M., Horii A., Uno A., Yamatodani A., and Matsunaga T. Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin-induced pica in rats. Methods Find. Exp. Clin. Pharmacol. 17 (1995) 647-652
54. Tanihata S., Oda S., Kakuta S., and Uchiyama T. Antiemetic effect of a tachykinin NK1 receptor antagonist GR205171 on cisplatin-induced early and delayed emesis in the pigeon. Eur. J. Pharmacol. 461 (2003) 197-206
55. Wang Y., and Aggarwal S.K. Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity. Anticancer Drugs 8 (1997) 853-858
56. Yamano M., Kamato T., and Miyata K. Participation of a cholinergic mechanism in 5-hydroxytryptamine (5-HT)3 and 5-HT4 receptor-mediated stimulation of gastric emptying in rats. Arzneimittelforschung 47 (1997) 1242-1246